SCHEMBL10150201

SCHEMBL10150201

Cc1cc(C)c2c(c1Cl)CC(=O)CCCC/C=C/C[C@@H](C)OC2=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 4/20 0.48
MKNK2 Q9HBH9 2/20 0.44
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
HSP90AA1 P07900 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ESR2 Q92731 2/20 0.38
MAOA P21397 3/20 0.36
F13A1 P00488 1/20 0.36
TGM2 P21980 1/20 0.36
CYP3A4 P08684 2/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
PTK2B Q14289 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150094 0.83 HSP90AB1 (0.70) HSP90AB1MKNK2ALDH1A1LMNAHSP90AA1
SCHEMBL10150178 0.82 HSP90AB1 (0.71) HSP90AB1MKNK2ALDH1A1HSP90AA1MAOA
SCHEMBL10150157 0.82 HSP90AB1 (0.71) HSP90AB1MKNK2ALDH1A1HSP90AA1MAOA
SCHEMBL10150204 0.81 MKNK2 (0.45) HSP90AB1MKNK2ALDH1A1LMNAHSP90AA1
SCHEMBL10150190 0.78 HSP90AB1 (0.54) HSP90AB1MKNK2ALDH1A1HSP90AA1MAOA
SCHEMBL10150849 0.77 HSP90AB1 (0.47) HSP90AB1MKNK2MAOAMKNK1FLT3
SCHEMBL14155862 0.77 MKNK2 (0.41) HSP90AB1MKNK2MAOAF13A1TGM2
SCHEMBL10150208 0.76 HSP90AB1 (0.48) HSP90AB1MKNK2MAOAMKNK1FLT3
SCHEMBL10150141 0.72 HSP90AB1 (0.84) HSP90AB1MKNK2ALDH1A1HSP90AA1MAOA
SCHEMBL10150206 0.71 HSP90AB1 (0.44) HSP90AB1MKNK2MAOAMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-8329683-B2 Treatment of neurofibromatosis with radicicol and its derivatives NEXGENIX PHARMACEUTICALS, LLC (US) 2012-12-11 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AB1 1/4885MKNK2 12/4885ALDH1A1 3243/4885
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives HSP90AB2P, HSP90AA1, HSPA2 HSP90AB1 4/4885MKNK2 2172/4885ALDH1A1 1005/4885
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AB1 1/4885MKNK2 12/4885ALDH1A1 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.